Rochester, MN, USA—Resoundant, Inc. announced today the appointment of Roderic I. Pettigrew, MD, PhD to its Board of Directors.
"We’re honored and thrilled to have Dr. Pettigrew join the Resoundant Board," said Richard L. Ehman, MD, professor of Radiology and the Blanche R. & Richard J. Erlanger Professor of Medical Research at Mayo Clinic and CEO of Resoundant, Inc.
“Dr. Pettigrew brings a remarkable combination of technologic, scientific, and global policy expertise to our team. He is a true visionary who has guided one of the most innovative and transformative medical portfolios in the world. His insight will be a tremendous asset to Resoundant.”
Members of the Resoundant Board Directors provide leadership and guidance in support of the overarching mission of the company: to radically advance patient care through exploration, development, and validation of high–impact applications of MR Elastography.
“Dr. Pettigrew joins the Resoundant team at an exciting time for the company,” said Jeffrey Bolton, Chair of the Resoundant Board of Directors and Chief Administrative Officer at Mayo Clinic. “The global market for MR Elastography is strong and the company is introducing important advances that are expanding the diagnostic capabilities.”
Dr. Pettigrew, PhD, MD, currently serves as CEO of Engineering Health (EnHealth) and executive dean for Engineering Medicine (EnMed) at Texas A&M and Houston Methodist Hospital. He was the founding Director of the U.S. National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the NIH, where he oversaw $5 billion in research investments. He is credited with building NIBIB into the signature NIH institute for medical innovation. Of note, under Dr Pettigrew’s leadership, NIBIB produced more patents per appropriated dollar than any other institute or agency across the U.S. federal government.
As CEO of Engineering Health (EnHealth) and executive dean for Engineering Medicine (EnMed) at Texas A&M and Houston Methodist Hospital, Dr. Roderic I. Pettigrew’s newest undertaking represents the world’s first initiative to holistically integrate engineering into all of the colleges of a university that are a part of the health care enterprise. EnMed is the first constituent initiative, creating a new school that integrates engineering into medical training to develop a new kind of engineering-minded physician, or Physcianeer, who invents solutions to healthcare problems. Of note, an invention is required of each EnMed graduate who will earn both MD and MEng degrees in 4 years.
Dr Pettigrew’s expertise is in health technologies emerging from the convergence of the life sciences, the physical sciences and engineering. An MIT graduate (PhD ’77) who finished his medical training at UCSD (’83), he is known internationally for his pioneering work involving four-dimensional imaging of the cardiovascular system using magnetic resonance (MRI). His current knowledge base also includes nanotechnology, regenerative medicine, and point-of-care technologies.
He has been elected to membership in the National Academy of Medicine, the National Academy of Engineering, the National Academy of Inventors and the National Academy of Sciences, India. Other awards include the Pierre Galletti Award (highest honor) of the American Institute of Medical and Biological Engineering, the Inaugural Gold Medal of the Academy of Radiology Research, the Distinguished Service Medal of the International Society of Magnetic Resonance in Medicine, the Spirit of the Heart Award of the ABC, the Pritzker Distinguished Achievement Award of the Biomedical Engineering Society, the Gold Medal of the Radiological Society of North America, and the Arthur M. Bueche Award of the National Academy of Engineering.
Additional advisory service includes the Phil and Penny Knight Institute for Accelerating Scientific Impact External Advisory Board, and the Stand Up To Cancer Advisory Board.
About Resoundant, Inc. Resoundant, Inc. is a medical technology company dedicated to improving patient care and diagnosis accuracy by making Magnetic Resonance Elastography (MRE) available around the world. Resoundant is based in Rochester, MN and was founded by Mayo Foundation for Medical Education & Research, Mayo Clinic physicians and researchers. MR Elastography is widely available to clinicians at over 1,500 Radiology and imaging centers across the globe. Clinicians and patients can find U.S. locations at MRE:connect (www.resoundant.com/mre-connect). MRE is also recognized in a number of multidisciplinary clinical guidelines for routine liver fibrosis assessment, particularly in suspected cases of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The American College of Radiology also issued Appropriateness Criteria® that identifies MRE as the most accurate and applicable noninvasive liver fibrosis exam. MRE obtaining a Category I CPT® code (76391) in 2019 and is currently covered by numerous public and private insurance plans. For more information, go to http://www.resoundant.com